This clinical trial is focused on studying a type of skin cancer called melanoma, specifically in cases where the cancer is advanced and cannot be removed by surgery. The study is investigating the effectiveness of a new treatment combination. The treatment involves two medications: IO102-IO103 and pembrolizumab. Pembrolizumab is already used in treating melanoma, while IO102-IO103 is being tested to see if it can improve outcomes when used together with pembrolizumab.

The purpose of the study is to compare the combination of IO102-IO103 and pembrolizumab against pembrolizumab alone. Participants in the study will receive either the combination treatment or pembrolizumab by itself. The study will monitor how long patients live without the cancer getting worse, which is known as progression-free survival. The trial will also look at other outcomes, such as the overall response rate, which measures how many patients experience a reduction in cancer size, and overall survival, which tracks how long patients live after starting the treatment.

Participants will be randomly assigned to one of the two treatment groups and will receive their treatment through injections. The study will continue for a period of up to 24 months, during which time patients will be regularly monitored to assess the effectiveness and safety of the treatments. This trial aims to provide valuable information on whether the new combination treatment can offer better results for patients with advanced melanoma.